Results 81 to 90 of about 8,133 (247)

Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo, Filipa Sofia Simas, Angela Ghiletchi, João Oliveira Torres, José Silva‐Nunes   +4 more
wiley   +1 more source

Abnormal release of incretins and cortisol after oral glucose in subjects with insulin-resistant myotonic dystrophy [PDF]

, 2002
Objective: Although the incretins, gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), as well as glucagon and cortisol, are known to influence islet function, the role of these hormones in conditions of insulin resistance and ...
Forsberg, H, Seckl, Jonathan R, Seckl, JR, Olsson, Tommy, Holst, Jens Juul, Cederquist, Kristina, Holst, JJ, Ahrén, Bo, Ahrén, Bo,, Forsberg, Hakan, Olsson, T, Johansson, Asa, Lund University., Cederquist, K, Johansson, A   +14 more
core   +1 more source

Role of incretin based therapies in the treatment of diabetic kidney disease

Сахарный диабет, 2018
Diabetic kidney disease (DKD), a serious microvascular complication of diabetes mellitus is a leading cause of end-stage renal disease and is associated with an increased risk of cardiovascular morbidity and mortality.
Paola Fioretto, Andrea Frascati
doaj   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

The Regulation of Metabolic Homeostasis by Incretins and the Metabolic Hormones Produced by Pancreatic Islets [PDF]

In healthy humans, the complex biochemical interplay between organs maintains metabolic homeostasis and pathological alterations in this process result in impaired metabolic homeostasis, causing metabolic diseases such as diabetes and obesity, which are ...
Steve Bain, Venkat Kanamarlapudi
core   +1 more source

Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients

Сахарный диабет, 2014
Optimizing treatments for type 2 diabetes mellitus (T2DM) remains an urgent issue. In addition to T2DM treatment strategies, such as glycaemic goals (glucose and glycated haemoglobin ?
Alina Babenko, Elena Ivanovna Krasilnikova, Nikolay Pavlovich Likhonosov, Anna Pavlovna Likhonosova, Elena Nikolaevna Grineva   +4 more
doaj   +1 more source

Responses to GLP‐1RA in White and Black Adults With Obesity: Insights From Generalized Additive Mixed Models of EHR Data

Obesity, EarlyView.
ABSTRACT Objective This study examined racial differences in weight loss and clinical response to glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) therapy among adults with obesity using real‐world data. Methods We retrospectively analyzed our institution's Research Data Warehouse (RDW) containing deidentified data from electronic health records ...
Jordan H. Mallette, Joshua S. Speed, Seth T. Lirette, Daniel Moore, John S. Clemmer   +4 more
wiley   +1 more source

Physiology and pathophysiology of incretins in the kidney [PDF]

, 2014
Purpose of reviewIncretin-based therapy with glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors is considered a promising therapeutic option for type 2 diabetes mellitus.
Reichetzeder, Christoph, Hocher, Berthold (Prof.), von Websky, Karoline   +2 more
core   +1 more source

Glucose metabolism and production of incretins in patients with obesity and type 2 diabetes mellitus after Biliopancreatic bypass surgery in the modification of Hess-Marceau the early stages of postoperative monitoring

Ожирение и метаболизм, 2015
Introduction: a significant improvement was shown in metabolic control at the early stages after BPD, which was associated with GLP-1 and was regardless of weight loss.Aim: to study the secretion of GLP-1, GIP, insulin and glucagon and their relationship
Ivan Ivanovich Dedov, Ekaterina Anatol'evna Troshina, Ekaterina Vladimirovna Ershova, Yuriy Ivanovich Yashkov   +3 more
doaj   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps

Obesity, EarlyView.
ABSTRACT The last 2 decades have seen historic advances in the treatment of obesity. We are entering an era of defining obesity not by weight‐based outcomes but by changes in body composition. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are forming the platform for obesity treatments based on their high level of efficacy. Body composition can
Robert L. Dubin, Tierra N. Sanders, Hunter M. Schwab, Steven B. Heymsfield, Frank L. Greenway   +4 more
wiley   +1 more source